JP2019513015A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513015A5
JP2019513015A5 JP2018547941A JP2018547941A JP2019513015A5 JP 2019513015 A5 JP2019513015 A5 JP 2019513015A5 JP 2018547941 A JP2018547941 A JP 2018547941A JP 2018547941 A JP2018547941 A JP 2018547941A JP 2019513015 A5 JP2019513015 A5 JP 2019513015A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
acid sequence
actriib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018547941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513015A (ja
JP6987072B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021958 external-priority patent/WO2017156488A2/en
Publication of JP2019513015A publication Critical patent/JP2019513015A/ja
Publication of JP2019513015A5 publication Critical patent/JP2019513015A5/ja
Priority to JP2021194152A priority Critical patent/JP7469284B2/ja
Application granted granted Critical
Publication of JP6987072B2 publication Critical patent/JP6987072B2/ja
Priority to JP2023198762A priority patent/JP7755634B2/ja
Priority to JP2025167026A priority patent/JP2026004489A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018547941A 2016-03-10 2017-03-10 アクチビン2型受容体結合タンパク質及びその使用 Active JP6987072B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021194152A JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用
JP2023198762A JP7755634B2 (ja) 2016-03-10 2023-11-24 アクチビン2型受容体結合タンパク質及びその使用
JP2025167026A JP2026004489A (ja) 2016-03-10 2025-10-03 アクチビン2型受容体結合タンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306354P 2016-03-10 2016-03-10
US62/306,354 2016-03-10
PCT/US2017/021958 WO2017156488A2 (en) 2016-03-10 2017-03-10 Activin type 2 receptor binding proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021194152A Division JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2019513015A JP2019513015A (ja) 2019-05-23
JP2019513015A5 true JP2019513015A5 (https=) 2020-04-23
JP6987072B2 JP6987072B2 (ja) 2021-12-22

Family

ID=59790844

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018547941A Active JP6987072B2 (ja) 2016-03-10 2017-03-10 アクチビン2型受容体結合タンパク質及びその使用
JP2021194152A Active JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用
JP2023198762A Active JP7755634B2 (ja) 2016-03-10 2023-11-24 アクチビン2型受容体結合タンパク質及びその使用
JP2025167026A Pending JP2026004489A (ja) 2016-03-10 2025-10-03 アクチビン2型受容体結合タンパク質及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021194152A Active JP7469284B2 (ja) 2016-03-10 2021-11-30 アクチビン2型受容体結合タンパク質及びその使用
JP2023198762A Active JP7755634B2 (ja) 2016-03-10 2023-11-24 アクチビン2型受容体結合タンパク質及びその使用
JP2025167026A Pending JP2026004489A (ja) 2016-03-10 2025-10-03 アクチビン2型受容体結合タンパク質及びその使用

Country Status (19)

Country Link
US (4) US10307455B2 (https=)
EP (2) EP3426680B1 (https=)
JP (4) JP6987072B2 (https=)
KR (4) KR102866147B1 (https=)
CN (2) CN116284392A (https=)
AU (1) AU2017230091B2 (https=)
BR (1) BR112018067813A2 (https=)
CA (1) CA3015277A1 (https=)
DK (1) DK3426680T3 (https=)
ES (1) ES2987504T3 (https=)
FI (1) FI3426680T3 (https=)
HR (1) HRP20241557T1 (https=)
HU (1) HUE069467T2 (https=)
LT (1) LT3426680T (https=)
PL (1) PL3426680T3 (https=)
PT (1) PT3426680T (https=)
RS (1) RS66251B1 (https=)
SI (1) SI3426680T1 (https=)
WO (1) WO2017156488A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116284392A (zh) 2016-03-10 2023-06-23 艾科赛扬制药股份有限公司 活化素2型受体结合蛋白及其用途
JP7669291B2 (ja) * 2019-05-30 2025-04-28 アクセレロン ファーマ インコーポレーテッド Actrii結合性タンパク質及びその使用
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
US20230174620A1 (en) * 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
EP4252782A4 (en) * 2020-11-30 2025-12-10 Cspc Megalith Biopharmaceutical Co Ltd ANTI-CLDN18.2 ANTIBODY, DRUG CONJUGATE, RELATED PREPARATION METHOD AND ASSOCIATED USE
MX2023014761A (es) * 2021-06-11 2024-01-19 Acceleron Pharma Inc Proteínas actrii y usos de las mismas.
JP2025529933A (ja) 2022-08-26 2025-09-09 バーサニス・バイオ・インコーポレイテッド ActRII抗体固定単位用量の治療
WO2025027052A1 (en) 2023-07-31 2025-02-06 Sixpeaks Bio Ag Antibody conjugates and fusion proteins

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
WO1997021728A1 (en) * 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
JP2000515003A (ja) 1996-05-20 2000-11-14 ノボ ノルディスク アクティーゼルスカブ タンパク質加水分解物を得る方法
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
RU2221809C2 (ru) 1997-10-03 2004-01-20 Тугаи Сейяку Кабусики Кайся Способ получения природного гуманизированного антитела
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
ZA200503075B (en) 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
RU2322261C2 (ru) 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
EP1740609A2 (en) 2004-04-27 2007-01-10 Research Development Foundation Antagonism of tgf-beta superfamily receptor signaling
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII受容体ポリペプチド、方法、および組成物
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AU2005272646A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
CA2538208A1 (en) 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2007067616A2 (en) 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
WO2007109668A2 (en) 2006-03-20 2007-09-27 The Uab Research Foundation Compositions and methods for improving bone mass through modulation of novel receptors of pth and fragments thereof
EP2052088A2 (en) 2006-08-02 2009-04-29 Genizon Biosciences Genemap of the human genes associated with psoriasis
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
EA018221B1 (ru) * 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
EP2238154B1 (en) 2008-01-18 2015-09-16 Bio-Rad Laboratories, Inc. Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
JP5611222B2 (ja) 2008-11-26 2014-10-22 アムジエン・インコーポレーテツド アクチビンiib受容体ポリペプチドの変異体及びその使用
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
PE20120532A1 (es) 2009-04-27 2012-05-18 Novartis Ag ANTICUERPOS ANTI-ActRIIB
ITAN20090010U1 (it) 2009-04-27 2010-10-28 Arnaldo Sorci Staffa di bloccaggio protettiva
EP3202459B1 (en) 2009-09-09 2021-04-14 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
EP2497168A1 (en) 2009-11-05 2012-09-12 The Regents of the University of California Semipolar {20-21} iii-nitride laser diodes with etched mirrors
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
EP2595657A4 (en) * 2010-07-22 2015-09-23 Univ California ANTI-TUMOR ANTIGEN ANTIBODIES AND USE PROCESSES
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
TW201249867A (en) * 2011-04-01 2012-12-16 Astellas Pharma Inc Novel anti-human il-23 receptor antibody
JP6472999B2 (ja) * 2011-07-01 2019-02-20 ノバルティス アーゲー 代謝障害を治療するための方法
BR112014000392A2 (pt) * 2011-07-14 2017-02-21 Pfizer tratamento com anticorpos anti-pcsk9
US8765385B2 (en) * 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013063536A1 (en) * 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
HK1203384A1 (en) 2011-12-19 2015-12-11 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US9029510B2 (en) 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof
NZ703724A (en) * 2012-06-11 2017-06-30 Amgen Inc Dual receptor antagonistic antigen-binding proteins and uses thereof
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
JP6049767B2 (ja) 2013-02-01 2016-12-21 株式会社ブリリアントサービス 栽培システム、栽培プログラム、および栽培方法
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
HK1221908A1 (zh) 2013-04-29 2017-06-16 Adimab, Llc 多特异(polyspecificity)试剂,其制备方法和用途
HK1219280A1 (zh) 2013-08-14 2017-03-31 Novartis Ag 治疗偶发性包涵体肌炎之方法
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
TN2017000217A1 (en) 2014-12-08 2018-10-19 Novartis Ag Myostatin or activin antagonists for the treatment of sarcopenia
CN116284392A (zh) 2016-03-10 2023-06-23 艾科赛扬制药股份有限公司 活化素2型受体结合蛋白及其用途
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Similar Documents

Publication Publication Date Title
JP2024026159A5 (https=)
JP2019513015A5 (https=)
CN109311971B (zh) 抗TL1A/抗TNF-α双特异性抗原结合蛋白及其用途
TWI767174B (zh) 異二聚免疫球蛋白
KR101852915B1 (ko) 과립구-대식세포 콜로니 자극 인자에 대한 항체
AU2021200348A1 (en) Binding molecules with modified J-chain
JP2022534966A5 (https=)
TWI815306B (zh) PD-1/TGF-beta四價雙特異性抗體、其製備方法和用途
CN115605594A (zh) 抗igf-1受体人源化抗体
CA3064298A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
WO2021013142A1 (zh) 抗4-1bb抗体、其抗原结合片段及双特异性抗体
JP2019515676A5 (https=)
KR20230141817A (ko) 이중특이 항체
WO2019080909A1 (en) TARGETING THERAPEUTIC ANTIBODY RANKL
JP2021500895A5 (https=)
CN113166239B (zh) 抗il-17a抗体及其应用
JP2022534514A5 (https=)
TW202535947A (zh) CD33抗體、CD33/Vδ2多特異性抗體及其用途
CN115811987A (zh) 抗神经酰胺抗体
AU2023291634C9 (en) Follistatin fusion proteins
US20260109769A1 (en) Pd-1 bnding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use
CN121399157A (zh) 淋巴毒素β受体激动剂结合蛋白
BR122025021892A2 (pt) Células hospedeiras
HK1212719B (zh) 全人源抗rankl抗体